Table 3 Medications on admission and at discharge.

From: Five-year outcomes in patients with multivessel coronary artery disease undergoing surgery or percutaneous intervention

Medications on admission

Overall (1035)

CABG (356)

PCI (679)

P value

Statin; n (%)

911 (88.0)

287 (80.6)

624 (91.9)

 < 0.01

ACE inhibitor; n (%)

664 (64.2)

199 (55.9)

465 (68.5)

 < 0.01

ARB; n (%)

209 (20.2)

76 (21.3)

133 (19.6)

0.50

Beta-blocker; n (%)

785 (75.8)

264 (74.2)

521 (76.7)

0.36

Medications at discharge

Overall (993)

CABG (339)

PCI (654)

P value

Aspirin; n (%)

933 (94.0)

302 (89.1)

631 (96.5)

 < 0.01

P2Y12 inhibitors; n (%)

706 (71.1)

71 (20.9)

635 (97.1)

 < 0.01

VKA; n (%)

52 (5.2)

29 (8.6)

23 (3.5)

 < 0.01

NOAC; n (%)

238 (24.0)

52 (15.3)

186 (28.4)

 < 0.01

Statin; n (%)

922 (92.9)

294 (86.7)

628 (96.0)

 < 0.01

ACE inhibitor; n (%)

685 (69.0)

206 (60.8)

479 (73.2)

 < 0.01

ARB; n (%)

229 (23.1)

85 (25.1)

144 (22.0)

0.28

Beta-blocker; n (%)

798 (80.4)

270 (79.6)

528 (80.7)

0.68

Loop diuretic; n (%)

662 (66.7)

228 (67.3)

434 (66.4)

0.78

Aldosterone antagonist; n (%)

230 (23.2)

43 (12.7)

187 (28.6)

 < 0.01

  1. CABG coronary artery bypass grafting, PCI percutaneous coronary intervention, P2Y12 inhibitors clopidogrel, prasugrel, ticagrelor, ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, NOAC novel oral anticoagulants, VKA Vitamin K antagonists.
Back to article page